Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents

References

• Sakr A, Brégeon F, Mège JL, et al. Staphylococcus aureus nasal colonization: an update on mechanisms, epidemiology, risk factors, and subsequent infections. Front Microbiol. 2018;9:2419. doi: 10.3389/fmicb.2018.02419
   PubMed Web of Science ®Google Scholar
• Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–661. doi: 10.1128/CMR.00134-14
   PubMed Web of Science ®Google Scholar
• Kourtis AP, Hatfield K, Baggs J, et al. Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible staphylococcus aureus bloodstream infections — United States. MMWR Morb Mortal Wkly Rep. 2019;68(9):214–219. Ed.^(Eds)
   PubMed Web of Science ®Google Scholar
• Cluff LE, Reynolds RC, Page DL, et al. Staphylococcal bacteremia and altered host resistance. Ann internal med. 1968;69(5):859–873. doi: 10.7326/0003-4819-69-5-859
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362–386. doi: 10.1128/CMR.05022-11
   PubMed Web of Science ®Google Scholar
• Eriksen KR, Erichsen I. Resistance to methicillin, isoxazolyl penicillins, and cephalothin in staphylococcus aureus. Acta Pathol Microbiol Scand. 1964;62(2):255–275. doi: 10.1111/apm.1964.62.2.255
   PubMedGoogle Scholar
• Harkins CP, Pichon B, Doumith M, et al. Methicillin-resistant staphylococcus aureus emerged long before the introduction of methicillin into clinical practice. Genome Biol. 2017;18(1):130. doi: 10.1186/s13059-017-1252-9
   PubMedGoogle Scholar
• Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in staphylococcus aureus. Antimicrob Agents Chemother. 2000;44(6):1549–1555. doi: 10.1128/AAC.44.6.1549-1555.2000
   PubMed Web of Science ®Google Scholar
• Opal SM, Pop-Vicas A. 18 - molecular mechanisms of antibiotic resistance in bacteria. In: Bennett J, Dolin R Blaser M, editors Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Eighth Edition). ed. Philadelphia: W.B. Saunders; 2015. p. 235–251.e233.
   Google Scholar
• Souli M, Ruffin F, Choi SH, et al. Changing characteristics of staphylococcus aureus bacteremia: results from a 21-year, prospective, longitudinal study. Clin Infect Dis. 2019;69(11):1868–1877. doi: 10.1093/cid/ciz112
   PubMed Web of Science ®Google Scholar
• Report from the NNIS System A. National Nosocomial Infections Surveillance (NNIS) National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–485. doi: 10.1016/j.ajic.2004.10.001
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26(2):166–174. doi: 10.1086/502522
   PubMed Web of Science ®Google Scholar
• Antibiotic resistance threats in the U.S. Centers For Disease Control And Prevention (2019). 2019.
   Google Scholar
• Hassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management and treatment. Crit Care. 2017;21(1):211. doi: 10.1186/s13054-017-1801-3
   PubMedGoogle Scholar
• Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi: 10.1016/S0140-6736(21)02724-0
   PubMed Web of Science ®Google Scholar
• Evans L, Rhodes A, Alhazzani W, et al. Executive summary: surviving sepsis campaign: international guidelines for the management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):1974–1982. doi: 10.1097/CCM.0000000000005357
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. Clinl Infect Dis. 2010;50(2):133–164. doi: 10.1086/649554
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clinl Infect Dis. 2004;39(9):1267–1284. doi: 10.1086/425368
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children. Clinl Infect Dis. 2011;52(3):e18–e55. doi: 10.1093/cid/ciq146
   PubMed Web of Science ®Google Scholar
• Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132(15):1435–1486. doi: 10.1161/CIR.0000000000000296
   PubMed Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200(7):e45–e67. doi: 10.1164/rccm.201908-1581ST
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv41–51. doi: 10.1093/jac/dkq254
   PubMed Web of Science ®Google Scholar
• Falagas ME, Manta KG, Ntziora F, et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58(2):273–280. doi: 10.1093/jac/dkl219
   PubMed Web of Science ®Google Scholar
• Low DE, File TM Jr., Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii33–44. doi: 10.1093/jac/dkr097
   PubMed Web of Science ®Google Scholar
• McCreary EK, Kullar R, Geriak M, et al. Multicenter cohort of patients with methicillin-resistant staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. Open Forum Infect Dis. 2020;7(1):ofz538. doi: 10.1093/ofid/ofz538
   PubMed Web of Science ®Google Scholar
• Pintado V, Pazos R, Jiménez-Mejías ME, et al. Linezolid for therapy of staphylococcus aureus meningitis: a cohort study of 26 patients. Infect Dis. 2020;52(11):808–815. doi: 10.1080/23744235.2020.1789212
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv53–iv65. doi: 10.1093/jac/dkq255
   PubMed Web of Science ®Google Scholar
• Griffith RS, Peck FB Jr. Vancomycin, a new antibiotic. III. Preliminary clinical and laboratory studies. Antibiot Annu. 1955;3:619–622.
   PubMedGoogle Scholar
• Lechevalier MP, Prauser H, Labeda DP, et al. Two new genera of nocardioform actinomycetes: amycolata gen. nov. And Amycolatopsis gen. nov. Int J Syst Evol Microbiol. 1986;36(1):29–37. doi: 10.1099/00207713-36-1-29
   Google Scholar
• Koyama N, Inokoshi J, Tomoda H. Anti-infectious agents against MRSA. Molecules. 2012;18(1):204–224. doi: 10.3390/molecules18010204
   PubMed Web of Science ®Google Scholar
• McDanel JS, Perencevich EN, Diekema DJ, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61(3):361–367. doi: 10.1093/cid/civ308
   PubMed Web of Science ®Google Scholar
• Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible staphylococcus aureus bacteremia. BMC Infect Dis. 2011;11(1):279. doi: 10.1186/1471-2334-11-279
   PubMedGoogle Scholar
• Levine DP. Vancomycin: a history. Clinl Infect Dis. 2006;42(Supplement_1):S5–S12. doi: 10.1086/491709
   PubMedGoogle Scholar
• Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017;102(3):459–469. doi: 10.1002/cpt.726
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734–744. doi: 10.1128/AAC.01568-12
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5):621–629. doi: 10.1093/cid/cir895
   PubMed Web of Science ®Google Scholar
• Magill SS, O’Leary E, Ray SM, et al. Antimicrobial use in US hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011. Clinl Infect Dis. 2021;72(10):1784–1792. doi: 10.1093/cid/ciaa373
   PubMed Web of Science ®Google Scholar
• Pais GM, Liu J, Zepcan S, et al. Vancomycin-induced kidney injury: animal models of Toxicodynamics, mechanisms of injury, human translation, and potential strategies for prevention. Pharmacother J Human Pharmacol Drug Ther. 2020;40(5):438–454. doi: 10.1002/phar.2388
   Google Scholar
• Sokol PP. Mechanism of vancomycin transport in the kidney: studies in rabbit renal brush border and basolateral membrane vesicles. J Pharmacol Exp Ther. 1991;259(3):1283–1287.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Takano M, Yasuhara M, et al. In-vivo clearance study of vancomycin in rats. J Pharm Pharmacol. 1996;48(11):1197–1200. doi: 10.1111/j.2042-7158.1996.tb03920.x
   PubMed Web of Science ®Google Scholar
• Rhodes NJ, Prozialeck WC, Lodise TP, et al. Evaluation of vancomycin exposures associated with elevations in novel urinary biomarkers of acute kidney injury in vancomycin-treated rats. Antimicrob Agents Chemother. 2016;60(10):5742–5751. doi: 10.1128/AAC.00591-16
   PubMed Web of Science ®Google Scholar
• Luque Y, Louis K, Jouanneau C, et al. Vancomycin-associated cast nephropathy. J Am Soc Nephrol. 2017;28(6):1723–1728. doi: 10.1681/ASN.2016080867
   PubMed Web of Science ®Google Scholar
• Shah-Khan F, Scheetz MH, Ghossein C. Biopsy-proven acute tubular necrosis due to vancomycin toxicity. Int J Nephrol. 2011;2011:1–4. doi: 10.4061/2011/436856
   Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-system Pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98. doi: 10.2146/ajhp080434
   PubMedGoogle Scholar
• Vancomycin hydrochloride [package insert]. Hospira Lake Forest IL; 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/062911s035lbl.pdf
   Google Scholar
• Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis. 2007;45(Supplement_3):S191–S195. doi: 10.1086/519470
   PubMedGoogle Scholar
• Beach JE, Perrott J, Turgeon RD, et al. Penetration of vancomycin into the cerebrospinal fluid: a systematic review. Clin Pharmacokinet. 2017;56(12):1479–1490. doi: 10.1007/s40262-017-0548-y
   PubMed Web of Science ®Google Scholar
• Cooper GL, Given DB. Vancomycin: a comprehensive review of 30 years of clinical experience. Indianapolis: Park Row Publishers; 1986.
   Google Scholar
• Albanèse J, Léone M, Bruguerolle B, et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother. 2000;44(5):1356–1358. doi: 10.1128/AAC.44.5.1356-1358.2000
   PubMed Web of Science ®Google Scholar
• Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996;38(5):865–869. doi: 10.1093/jac/38.5.865
   PubMed Web of Science ®Google Scholar
• Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993;37(2):281–286. doi: 10.1128/AAC.37.2.281
   PubMed Web of Science ®Google Scholar
• Scheetz MH, Wunderink RG, Postelnick MJ, et al. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant staphylococcus aureus pneumonia. Pharmacother J Human Pharmacol Drug Ther. 2006;26(4):539–550. doi: 10.1592/phco.26.4.539
   Google Scholar
• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the infectious Diseases Society of America, the pediatric infectious Diseases Society, and the Society of infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–864. doi: 10.1093/ajhp/zxaa036
   PubMed Web of Science ®Google Scholar
• Neely MN, Youn G, Jones B, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309–316. doi: 10.1128/AAC.01653-13
   PubMed Web of Science ®Google Scholar
• Pai MP, Neely M, Rodvold KA, et al. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;77:50–57. doi: 10.1016/j.addr.2014.05.016
   PubMed Web of Science ®Google Scholar
• Horey A, Mergenhagen KA, Mattappallil A. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran’s population: a retrospective analysis. Ann Pharmacother. 2012;46(11):1477–1483. doi: 10.1345/aph.1R158
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507–514. doi: 10.1086/600884
   PubMed Web of Science ®Google Scholar
• O’Donnell JN, Rhodes NJ, Miglis CM, et al. Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies. Int J Antimicrob Agents. 2018;51(2):239–243. doi: 10.1016/j.ijantimicag.2017.08.012
   PubMed Web of Science ®Google Scholar
• Cano EL, Haque NZ, Welch VL, et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database. Clin Ther. 2012;34(1):149–157. doi: 10.1016/j.clinthera.2011.12.013
   PubMed Web of Science ®Google Scholar
• Barriere SL, Stryjewski ME, Corey GR, et al. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the phase 3 ATTAIN studies. BMC Infect Dis. 2014;14(1):183. doi: 10.1186/1471-2334-14-183
   PubMedGoogle Scholar
• Aljefri DM, Avedissian SN, Rhodes NJ, et al. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69(11):1881–1887. doi: 10.1093/cid/ciz051
   PubMed Web of Science ®Google Scholar
• Liu J, Tong SYC, Davis JS, et al. Vancomycin exposure and acute kidney injury outcome: a snapshot from the CAMERA2 study. Open Forum Infect Dis. 2020;7(12):ofaa538. doi: 10.1093/ofid/ofaa538
   PubMed Web of Science ®Google Scholar
• Lodise TP, Scheetz M, Carreno JJ, et al. Associations between vancomycin exposure and acute kidney injury within the recommended area under the curve therapeutic exposure range among patients with methicillin-resistant staphylococcus aureus bloodstream infections. Open Forum Infect Dis. 2022;9(2):ofab651. doi: 10.1093/ofid/ofab651
   PubMed Web of Science ®Google Scholar
• Lodise TP, Rosenkranz SL, Finnemeyer M, et al. The Emperor’s new clothes: PRospective observational evaluation of the association between initial VancomycIn exposure and failure rates among ADult HospitalizEd patients with methicillin-resistant staphylococcus aureus bloodstream infections (PROVIDE). Clin Infect Dis. 2020;70(8):1536–1545. doi: 10.1093/cid/ciz460
   PubMed Web of Science ®Google Scholar
• Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62(2). doi: 10.1128/AAC.02042-17
   Web of Science ®Google Scholar
• Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother. 2012;56(2):634–638. doi: 10.1128/AAC.05609-11
   PubMed Web of Science ®Google Scholar
• Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654–1663. doi: 10.1128/AAC.01485-12
   PubMed Web of Science ®Google Scholar
• Gawronski KM, Goff DA, Brown J, et al. A stewardship program’s retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant staphylococcus aureus bacteremia and osteomyelitis. Clin Ther. 2013;35(6):772–779. doi: 10.1016/j.clinthera.2013.05.008
   PubMed Web of Science ®Google Scholar
• Jung Y, Song KH, Cho J, et al. Area under the concentration–time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2014;43(2):179–183. doi: 10.1016/j.ijantimicag.2013.10.017
   PubMed Web of Science ®Google Scholar
• Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59(5):666–675. doi: 10.1093/cid/ciu398
   PubMed Web of Science ®Google Scholar
• Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527–537. doi: 10.1001/jama.2020.0103
   PubMed Web of Science ®Google Scholar
• Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis. 2007;45(Suppl 3):S191–195. doi: 10.1086/519470
   PubMed Web of Science ®Google Scholar
• LaPlante KL, Rybak MJ. Impact of high-inoculum staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48(12):4665–4672. doi: 10.1128/AAC.48.12.4665-4672.2004
   PubMed Web of Science ®Google Scholar
• Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis. 2014;59(10):1455–1461. doi: 10.1093/cid/ciu583
   PubMed Web of Science ®Google Scholar
• Kuehl R, Morata L, Boeing C, et al. Defining persistent staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis. 2020;20(12):1409–1417. doi: 10.1016/S1473-3099(20)30447-3
   PubMed Web of Science ®Google Scholar
• Minejima E, Mai N, Bui N, et al. Defining the breakpoint duration of staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis. 2020;70(4):566–573. doi: 10.1093/cid/ciz257
   PubMed Web of Science ®Google Scholar
• Casapao AM, Lodise TP, Davis SL, et al. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother. 2015;59(6):2978–2985. doi: 10.1128/AAC.03970-14
   PubMed Web of Science ®Google Scholar
• Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord. 2001;1(2):181–199. doi: 10.2174/1568005014606099
   PubMedGoogle Scholar
• Linezolid [package insert]. (NY) NY: Pfizer; 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021130s032,021131s026,021132s031lbl.pdf
   Google Scholar
• Brickner SJ. 8.13 - Zyvox. In: Taylor J Triggle D, editors Comprehensive medicinal chemistry II. Oxford: Elsevier; 2007. p. 157–171.
   Google Scholar
• Diekema DJ, Jones RN. Oxazolidinones. Drugs. 2000;59(1):7–16. doi: 10.2165/00003495-200059010-00002
   PubMed Web of Science ®Google Scholar
• Martin J, Herberg J, Slatter J, et al. Although a novel microtiter-plate assay demonstrates that linezolid (PNU-100766) is a weak, competitive (reversible) inhibitor of human monoamine oxidase (MAO A), no clinical evidence of MAO a inhibition in clinical trials has been observed. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA; 1998.
   Google Scholar
• Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: Pharmacokinetic and Pharmacodynamic Evaluation of Coadministration with Pseudoephedrine HCl, Phenylpropanolamine HCl, and Dextromethorphan HBr. J Clin Pharmacol. 2001;41(5):563–572. doi: 10.1177/00912700122010302
   PubMed Web of Science ®Google Scholar
• Bai AD, McKenna S, Wise H, et al. Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants. JAMA Netw Open. 2022;5(12):e2247426–e2247426. doi: 10.1001/jamanetworkopen.2022.47426
   PubMed Web of Science ®Google Scholar
• Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723–2726. doi: 10.1128/AAC.46.8.2723-2726.2002
   PubMed Web of Science ®Google Scholar
• Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. J Am Med Assoc. 2001;285(10):1291. doi: 10.1001/jama.285.10.1291
   PubMed Web of Science ®Google Scholar
• Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clinl Infect Dis. 2002;34(5):695–698. doi: 10.1086/338403
   PubMed Web of Science ®Google Scholar
• Lima LS, Brito CA, Mattos K, et al. A retrospective cohort study to screen linezolid-induced thrombocytopenia in adult patients hospitalized in the Midwestern Region of Brazil. Hematol Transfus Cell Ther. 2020;42(3):230–237. doi: 10.1016/j.htct.2019.07.004
   PubMedGoogle Scholar
• Choi GW, Lee J-Y, Chang MJ, et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol. 2019;124(2):228–234. doi: 10.1111/bcpt.13123
   PubMed Web of Science ®Google Scholar
• Wicha SG, Mair A, Chiriac U, et al. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients. Int J Antimicrob Agents. 2022;59(5):106572. doi: 10.1016/j.ijantimicag.2022.106572
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(8):2034–2042. doi: 10.1093/jac/dks153
   PubMed Web of Science ®Google Scholar
• Lau C, Marriott D, Bui J, et al. Linezolid monitoring to MInimise toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring. Int J Antimicrob Agents. 2023;61(5):106783. doi: 10.1016/j.ijantimicag.2023.106783
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42(13):1129–1140. doi: 10.2165/00003088-200342130-00004
   PubMed Web of Science ®Google Scholar
• Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos. 2001;22(3):91–97. doi: 10.1002/bdd.255
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Rimmelé T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med. 2005;33(7):1529–1533. doi: 10.1097/01.CCM.0000168206.59873.80
   PubMed Web of Science ®Google Scholar
• Conte JE Jr., Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46(5):1475–1480. doi: 10.1128/AAC.46.5.1475-1480.2002
   PubMed Web of Science ®Google Scholar
• Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother. 2003;51(6):1431–1434. doi: 10.1093/jac/dkg262
   PubMed Web of Science ®Google Scholar
• Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother. 2006;50(12):3971–3976. doi: 10.1128/AAC.00051-06
   PubMed Web of Science ®Google Scholar
• Tsona A, Metallidis S, Foroglou N, et al. Linezolid penetration into cerebrospinal fluid and brain tissue. J Chemother. 2010;22(1):17–19. doi: 10.1179/joc.2010.22.1.17
   PubMed Web of Science ®Google Scholar
• Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(suppl_4):iv7–iv15. doi: 10.1093/jac/dkr072
   PubMedGoogle Scholar
• Rybak MJ, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother. 1998;42(3):721–724. doi: 10.1128/AAC.42.3.721
   PubMed Web of Science ®Google Scholar
• Andes D, van Ogtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002;46(11):3484–3489. doi: 10.1128/AAC.46.11.3484-3489.2002
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Batard E, Perez L, et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother. 2002;46(12):3706–3711. doi: 10.1128/AAC.46.12.3706-3711.2002
   PubMed Web of Science ®Google Scholar
• Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42(15):1411–1423. doi: 10.2165/00003088-200342150-00007
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious Diseases Society of America and the American Thoracic Society. Clinl Infect Dis. 2016;63(5):e61–e111. doi: 10.1093/cid/ciw353
   PubMed Web of Science ®Google Scholar
• Kato H, Hagihara M, Asai N, et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant staphylococcus aureus. J Glob Antimicrob Resist. 2021;24:98–105. doi: 10.1016/j.jgar.2020.12.009
   PubMed Web of Science ®Google Scholar
• Kalil AC, Klompas M, Haynatzki G, et al. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open. 2013;3(10):e003912. doi: 10.1136/bmjopen-2013-003912
   PubMed Web of Science ®Google Scholar
• Wang Y, Zou Y, Xie J, et al. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol. 2015;71(1):107–115. doi: 10.1007/s00228-014-1775-x
   PubMed Web of Science ®Google Scholar
• Jiang H, Tang RN, Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis. 2013;32(9):1121–1128. doi: 10.1007/s10096-013-1867-z
   PubMed Web of Science ®Google Scholar
• Wu C, Zhang X, Xie J, et al. Pharmacokinetic/Pharmacodynamic parameters of linezolid in the epithelial lining fluid of patients with sepsis. J Clin Pharmacol. 2022;62(7):891–897. doi: 10.1002/jcph.2031
   PubMed Web of Science ®Google Scholar
• Viale P, Pagani L, Cristini F, et al. Linezolid for the treatment of central nervous system infections in neurosurgical patients. Scand J Infect Dis. 2002;34(6):456–459. doi: 10.1080/00365540110080467
   PubMed Web of Science ®Google Scholar
• Kessler AT, Kourtis AP. Treatment of meningitis caused by methicillin-resistant staphylococcus aureus with linezolid. Infection. 2007;35(4):271–274. doi: 10.1007/s15010-007-6211-z
   PubMed Web of Science ®Google Scholar
• Kallweit U, Harzheim M, Marklein G, et al. Successful treatment of methicillin-resistant staphylococcus aureus meningitis using linezolid without removal of intrathecal infusion pump. Case report. J Neurosurg. 2007;107(3):651–653. doi: 10.3171/JNS-07/09/0651
   PubMed Web of Science ®Google Scholar
• Saito N, Aoki K, Sakurai T, et al. Linezolid treatment for intracranial abscesses caused by methicillin-resistant staphylococcus aureus–two case reports. Neurol Med Chir (Tokyo). 2010;50(6):515–517. doi: 10.2176/nmc.50.515
   PubMed Web of Science ®Google Scholar
• Rebai L, Fitouhi N, Daghmouri MA, et al. Linezolid for the treatment of postneurosurgical infection caused by methicillin-resistant staphylococcus. Surg Neurol Int. 2019;10:215. doi: 10.25259/SNI_455_2019
   PubMedGoogle Scholar
• Chen HA, Yang CJ, Tsai MS, et al. Linezolid as salvage therapy for central nervous system infections due to methicillin-resistant staphylococcus aureus at two medical centers in Taiwan. J Microbiol Immunol Infect. 2020;53(6):909–915. doi: 10.1016/j.jmii.2020.08.004
   PubMedGoogle Scholar
• Sipahi OR, Bardak-Ozcem S, Turhan T, et al. Vancomycin versus linezolid in the treatment of methicillin-resistant staphylococcus aureus meningitis. Surg Infect (Larchmt). 2013;14(4):357–362. doi: 10.1089/sur.2012.091
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant staphylococcus aureus infections. Clin Infect Dis. 2002;34(11):1481–1490. doi: 10.1086/340353
   PubMed Web of Science ®Google Scholar
• McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant staphylococcus aureus in elderly US patients. Clin Ther. 2007;29(3):469–477. doi: 10.1016/s0149-2918(07)80085-3
   PubMed Web of Science ®Google Scholar
• Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant staphylococcus aureus: treatment failure with Linezolid. Clinl Infect Dis. 2002;35(8):1018–1020. doi: 10.1086/342698
   PubMed Web of Science ®Google Scholar
• Muñoz P, De la Villa S, Martínez-Sellés M, et al. Linezolid for infective endocarditis: a structured approach based on a national database experience. Medicine (Baltimore). 2021;100(51):e27597. doi: 10.1097/MD.0000000000027597
   PubMed Web of Science ®Google Scholar
• Tascini C, Bongiorni MG, Doria R, et al. Linezolid for endocarditis: a case series of 14 patients. J Antimicrob Chemother. 2011;66(3):679–682. doi: 10.1093/jac/dkq506
   PubMed Web of Science ®Google Scholar
• Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J Antimicrob Chemother. 2000;46(4):523–526. doi: 10.1093/jac/46.4.523
   PubMed Web of Science ®Google Scholar
• Allen NE, Alborn WE, Hobbs JN. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother. 1991;35(12):2639–2642. doi: 10.1128/AAC.35.12.2639
   PubMed Web of Science ®Google Scholar
• Straus SK, Hancock REW. Mode of action of the new antibiotic for gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta - Biomembr. 2006;1758(9):1215–1223. doi: 10.1016/j.bbamem.2006.02.009
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Barry AL, Brown SD. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis. 2000;38(1):51–58. doi: 10.1016/S0732-8893(00)00164-4
   PubMed Web of Science ®Google Scholar
• Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical gram-positive organisms. J Antimicrob Chemother. 2004;53(4):669–674. doi: 10.1093/jac/dkh143
   PubMed Web of Science ®Google Scholar
• Wise R, Andrews JM, Ashby JP. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother. 2001;48(4):563–567. doi: 10.1093/jac/48.4.563
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother. 2002;49(3):467–470. doi: 10.1093/jac/49.3.467
   PubMed Web of Science ®Google Scholar
• Daptomycin [package insert]. Merck Rahway NJ; 2015. https://www.merck.com/product/usa/pi_circulars/c/cubicin/cubicin_pi.pdf
   Google Scholar
• Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47(4):1318–1323. doi: 10.1128/AAC.47.4.1318-1323.2003
   PubMed Web of Science ®Google Scholar
• He W, Zhang Y, Chen H, et al. Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials. J Antimicrob Chemother. 2014;69(12):3181–3189. doi: 10.1093/jac/dku277
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clinl Infect Dis. 2004;38(12):1673–1681. doi: 10.1086/420818
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Ambrose PG, Hammel JP, et al. Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations. Antimicrob Agents Chemother. 2015;60(3):1600–1607. doi: 10.1128/AAC.02967-15
   PubMed Web of Science ®Google Scholar
• Byren I, Rege S, Campanaro E, et al. Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother. 2012;56(11):5626–5632. doi: 10.1128/AAC.00038-12
   PubMed Web of Science ®Google Scholar
• Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008;62(9):1455–1464. doi: 10.1111/j.1742-1241.2008.01854.x
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by staphylococcus aureus. N Engl J Med. 2006;355(7):653–665. doi: 10.1056/NEJMoa053783
   PubMed Web of Science ®Google Scholar
• Woodworth JR, Nyhart EH Jr., Brier GL, et al. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1992;36(2):318–325. doi: 10.1128/AAC.36.2.318
   PubMed Web of Science ®Google Scholar
• Vilay AM, Grio M, Depestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med. 2011;39(1):19–25. doi: 10.1097/CCM.0b013e3181fa36fb
   PubMed Web of Science ®Google Scholar
• Piva S, Di Paolo A, Galeotti L, et al. Daptomycin plasma and CSF levels in patients with healthcare-associated meningitis. Neurocrit Care. 2019;31(1):116–124. doi: 10.1007/s12028-018-0657-y
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, VanPraagh ADG, et al. Inhibition of daptomycin by pulmonary surfactant: In Vitro modeling and clinical impact. J Infect Dis. 2005;191(12):2149–2152. doi: 10.1086/430352
   PubMed Web of Science ®Google Scholar
• Hanberger H, Nilsson LE, Maller R, et al. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother. 1991;35(9):1710–1716. doi: 10.1128/AAC.35.9.1710
   PubMed Web of Science ®Google Scholar
• Bush LM, Boscia JA, Wendeler M, et al. In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant staphylococcus aureus strains. Antimicrob Agents Chemother. 1989;33(8):1198–1200. doi: 10.1128/AAC.33.8.1198
   PubMed Web of Science ®Google Scholar
• D’Avolio A, Pensi D, Baietto L, et al. Daptomycin pharmacokinetics and pharmacodynamics in septic and critically ill patients. Drugs. 2016;76(12):1161–1174. doi: 10.1007/s40265-016-0610-3
   PubMed Web of Science ®Google Scholar
• Butterfield JM, Mueller BA, Patel N, et al. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Antimicrob Agents Chemother. 2013;57(2):864–872. doi: 10.1128/AAC.02000-12
   PubMed Web of Science ®Google Scholar
• Grégoire N, Marchand S, Ferrandière M, et al. Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. J Antimicrob Chemother. 2019;74(1):117–125. doi: 10.1093/jac/dky374
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant staphylococcus aureus bacteremia. Clinl Infect Dis. 2013;57(11):1568–1576. doi: 10.1093/cid/cit582
   PubMed Web of Science ®Google Scholar
• Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48(1):63–68. doi: 10.1128/AAC.48.1.63-68.2004
   PubMed Web of Science ®Google Scholar
• Aikawa N, Kusachi S, Mikamo H, et al. Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J Infect Chemother. 2013;19(3):447–455. doi: 10.1007/s10156-012-0501-9
   PubMed Web of Science ®Google Scholar
• Quist SR, Fierlbeck G, Seaton RA, et al. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections. Int J Antimicrob Agents. 2012;39(1):90–91. doi: 10.1016/j.ijantimicag.2011.08.007
   PubMed Web of Science ®Google Scholar
• Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract. 2009;63(3):368–375. doi: 10.1111/j.1742-1241.2008.01988.x
   PubMed Web of Science ®Google Scholar
• Konychev A, Heep M, Moritz RKC, et al. Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an Open-label, multicentre, randomized phase IIIb trial. Drugs Aging. 2013;30(10):829–836. doi: 10.1007/s40266-013-0114-8
   PubMed Web of Science ®Google Scholar
• Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis. 2013;56(11):1562–1569. doi: 10.1093/cid/cit112
   PubMed Web of Science ®Google Scholar
• Claeys KC, Zasowski EJ, Casapao AM, et al. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2016;60(10):5841–5848. doi: 10.1128/AAC.00227-16
   PubMed Web of Science ®Google Scholar
• Maraolo AE, Giaccone A, Gentile I, et al. Daptomycin versus vancomycin for the treatment of methicillin-resistant staphylococcus aureus bloodstream infection with or without endocarditis: a systematic review and meta-analysis. Antibiotics. 2021;10(8):1014. doi: 10.3390/antibiotics10081014
   Google Scholar
• Cojutti PG, Candoni A, Ramos-Martin V, et al. Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. J Antimicrob Chemother. 2017;72(8):2342–2350. doi: 10.1093/jac/dkx140
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Benziger DP, Yankelev S, et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50(10):3245–3249. doi: 10.1128/AAC.00247-06
   PubMed Web of Science ®Google Scholar
• Moise PA, Hershberger E, Amodio-Groton MI, et al. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009;43(7–8):1211–1219. doi: 10.1345/aph.1M085
   PubMed Web of Science ®Google Scholar
• Rose WE, Leonard SN, Sakoulas G, et al. Daptomycin activity against staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2008;52(3):831–836. doi: 10.1128/AAC.00869-07
   PubMed Web of Science ®Google Scholar
• Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2008;52(9):3061–3067. doi: 10.1128/AAC.00102-08
   PubMed Web of Science ®Google Scholar
• Dhand A, Sakoulas G. Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant staphylococcus aureus bacteremia. Clin Ther. 2014;36(10):1303–1316. doi: 10.1016/j.clinthera.2014.09.005
   PubMed Web of Science ®Google Scholar
• Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical staphylococcus aureus isolates (‘the MIC creep’): implications for therapy. F1000 Med Rep. 2012;4(4). doi: 10.3410/M4-4
   PubMedGoogle Scholar
• Jorgensen SCJ, Zasowski EJ, Trinh TD, et al. Daptomycin plus β-lactam combination therapy for methicillin-resistant staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study. Clinl Infect Dis. 2020;71(1):1–10. doi: 10.1093/cid/ciz746
   PubMed Web of Science ®Google Scholar
• Ortwine JK, Werth BJ, Sakoulas G, et al. Reduced glycopeptide and lipopeptide susceptibility in staphylococcus aureus and the “seesaw effect”: taking advantage of the back door left open? Drug Resist Updat. 2013;16(3):73–79. doi: 10.1016/j.drup.2013.10.002
   PubMed Web of Science ®Google Scholar
• Ceftaroline [package insert]. Allergan Madison NJ; 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200327s028lbl.pdf
   Google Scholar
• Duplessis C, Crum-Cianflone NF. Ceftaroline: a new cephalosporin with activity against methicillin-resistant staphylococcus aureus (MRSA). Clin Med Rev Ther. 2011 Feb 10;3:a2466. doi: 10.4137/CMRT.S1637
   PubMedGoogle Scholar
• Ge Y, Biek D, Talbot GH, et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52(9):3398–3407. doi: 10.1128/AAC.00149-08
   PubMed Web of Science ®Google Scholar
• Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005;49(8):3501–3512. doi: 10.1128/AAC.49.8.3501-3512.2005
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Ge Y, et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother. 2007;60(2):300–311. doi: 10.1093/jac/dkm150
   PubMed Web of Science ®Google Scholar
• Vidaillac C, Leonard SN, Rybak MJ. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant staphylococcus aureus (HA-MRSA) isolates. Int J Antimicrob Agents. 2010;35(6):527–530. doi: 10.1016/j.ijantimicag.2010.02.006
   PubMed Web of Science ®Google Scholar
• Saravolatz L, Pawlak J, Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010;54(7):3027–3030. doi: 10.1128/AAC.01516-09
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother. 2007;51(9):3397–3400. doi: 10.1128/AAC.01242-06
   PubMed Web of Science ®Google Scholar
• Blumenthal KG, Kuhlen JL Jr., Weil AA, et al. Adverse drug reactions associated with ceftaroline use: a 2-center retrospective cohort. J Allergy Clin Immunol Pract. 2016;4(4):740–746. doi: 10.1016/j.jaip.2016.03.008
   PubMed Web of Science ®Google Scholar
• Jain R, Chan JD, Rogers L, et al. High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Pharmacotherapy. 2014;34(7):758–763. doi: 10.1002/phar.1435
   PubMed Web of Science ®Google Scholar
• Jansen JW, Linneman TW, Tan X, et al. Comparison of adverse drug reactions between patients treated with ceftaroline or ceftriaxone: a single-center, matched cohort study. Open Forum Infect Dis. 2019;6(7):ofz279. doi: 10.1093/ofid/ofz279
   PubMed Web of Science ®Google Scholar
• Jansen JW, Moenster RP. Rate and incidence of adverse reactions associated with ceftaroline exposure: importance of cutaneous manifestations. Ann Pharmacother. 2018;52(3):235–239. doi: 10.1177/1060028017735629
   PubMed Web of Science ®Google Scholar
• Rimawi RH, Frenkel A, Cook PP. Ceftaroline - a cause for neutropenia. J Clin Pharm Ther. 2013;38(4):330–332. doi: 10.1111/jcpt.12062
   PubMed Web of Science ®Google Scholar
• Yam FK, Kwan BK. A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline. Am J Health Syst Pharm. 2014;71(17):1457–1461. doi: 10.2146/ajhp130474
   PubMed Web of Science ®Google Scholar
• Justo JA, Mayer SM, Pai MP, et al. Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects. Antimicrob Agents Chemother. 2015;59(7):3956–3965. doi: 10.1128/AAC.00498-15
   PubMed Web of Science ®Google Scholar
• Helfer VE, Zavascki AP, Zeitlinger M, et al. Population pharmacokinetic modeling and probability of target attainment of ceftaroline in brain and soft tissues. Antimicrob Agents Chemother. 2022;66(9):e0074122. doi: 10.1128/aac.00741-22
   PubMed Web of Science ®Google Scholar
• Riccobene TA, Pushkin R, Jandourek A, et al. Penetration of ceftaroline into the epithelial lining fluid of healthy adult subjects. Antimicrob Agents Chemother. 2016;60(10):5849–5857. doi: 10.1128/AAC.02755-15
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother. 2006;50(4):1376–1383. doi: 10.1128/AAC.50.4.1376-1383.2006
   PubMed Web of Science ®Google Scholar
• Das S, Li J, Iaconis J, et al. Ceftaroline fosamil doses and breakpoints for staphylococcus aureus in complicated skin and soft tissue infections. J Antimicrob Chemother. 2019;74(2):425–431. doi: 10.1093/jac/dky439
   PubMed Web of Science ®Google Scholar
• Bucheit J, Collins R, Joshi P. Methicillin-resistant staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy. Am J Health Syst Pharm. 2014;71(2):110–113. doi: 10.2146/ajhp130246
   PubMed Web of Science ®Google Scholar
• Cies JJ, Moore WS, Enache A, et al. Ceftaroline for suspected or confirmed invasive methicillin-resistant staphylococcus aureus: a pharmacokinetic case series. Pediatr Crit Care Med. 2018;19(6):e292–e299. doi: 10.1097/PCC.0000000000001497
   PubMed Web of Science ®Google Scholar
• Ho TT, Cadena J, Childs LM, et al. Methicillin-resistant staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67(5):1267–1270. doi: 10.1093/jac/dks006
   PubMed Web of Science ®Google Scholar
• Kuriakose SS, Rabbat M, Gallagher JC. Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis. J Antimicrob Chemother. 2015;70(3):953–954. doi: 10.1093/jac/dku464
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641–650. doi: 10.1086/655827
   PubMed Web of Science ®Google Scholar
• Jandourek A, Smith A, Llorens L, et al. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia. Hosp Pract (1995). 2014;42(1):75–78. doi: 10.3810/hp.2014.02.1094
   PubMedGoogle Scholar
• Zhong NS, Sun T, Zhuo C, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015;15(2):161–171. doi: 10.1016/S1473-3099(14)71018-7
   PubMed Web of Science ®Google Scholar
• File TM Jr., Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51(12):1395–1405. doi: 10.1086/657313
   PubMed Web of Science ®Google Scholar
• Ramani A, Udeani G, Evans J, et al. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience. J Chemother. 2014;26(4):229–234. doi: 10.1179/1973947814Y.0000000184
   PubMed Web of Science ®Google Scholar
• Kaye KS, Udeani G, Cole P, et al. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. Hosp Pract. 2015;43(3):144–149. doi: 10.1080/21548331.2015.1037228
   PubMedGoogle Scholar
• Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant staphylococcus aureus. Antimicrob Agents Chemother. 2004;48(8):2871–2875. doi: 10.1128/AAC.48.8.2871-2875.2004
   PubMed Web of Science ®Google Scholar
• Geriak M, Haddad F, Rizvi K, et al. Clinical data on Daptomycin plus ceftaroline versus Standard of Care Monotherapy in the treatment of methicillin-resistant staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02483-18. doi: 10.1128/AAC.02483-18. PMID: 30858203; PMCID: PMC6496065
   Web of Science ®Google Scholar
• Cies JJ, Moore WS, Enache A, et al. Ceftaroline cerebrospinal fluid Penetration in the treatment of a ventriculopleural shunt infection: a case report. J Pediatr Pharmacol Ther. 2020;25(4):336–339. doi: 10.5863/1551-6776-25.4.336
   PubMedGoogle Scholar
• Balouch MA, Bajwa RJ, Hassoun A. Successful use of ceftaroline for the treatment of MRSA meningitis secondary to an infectious complication of lumbar spine surgery. J Antimicrob Chemother. 2015;70(2):624–625. doi: 10.1093/jac/dku392
   PubMed Web of Science ®Google Scholar
• Holland TL, Cosgrove SE, Doernberg SB, et al. LB2302. Ceftobiprole compared to daptomycin with or without optional aztreonam for the treatment of complicated staphylococcus aureus (SAB): results of a phase 3, randomized, double-blind trial (ERADICATE). Open Forum Infect Dis. 2022;9(Suppl 2). doi: 10.1093/ofid/ofac492.1892
   Google Scholar
• Liapikou A, Cillóniz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015;9:4565–4572. doi: 10.2147/DDDT.S56616
   PubMedGoogle Scholar
• Turner NA, Zaharoff S, King H, et al. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials. 2022;23(1):407. doi: 10.1186/s13063-022-06370-1
   PubMed Web of Science ®Google Scholar
• Dalbavancin [package insert]. Allergan USA Inc Irvine CA; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021883s007lbl.pdf
   Google Scholar
• Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40(3):374–380. doi: 10.1086/427283
   PubMed Web of Science ®Google Scholar
• Hakim A, Braun H, Thornton D, et al. Successful treatment of methicillin-sensitive staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: a case report. Int J Infect Dis. 2020;91:202–205. doi: 10.1016/j.ijid.2019.12.008
   PubMed Web of Science ®Google Scholar
• Morrisette T, Miller MA, Montague BT, et al. On- and off-label utilization of dalbavancin and oritavancin for gram-positive infections. J Antimicrob Chemother. 2019;74(8):2405–2416. doi: 10.1093/jac/dkz162
   PubMed Web of Science ®Google Scholar
• Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections. Infect Dis Ther. 2019;8(2):171–184. doi: 10.1007/s40121-019-0247-0
   PubMed Web of Science ®Google Scholar
• Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General hospital of Vienna. Clin Infect Dis. 2018;67(5):795–798. doi: 10.1093/cid/ciy279
   PubMed Web of Science ®Google Scholar
• Tong SYC, Mora J, Bowen AC, et al. The staphylococcus aureus network adaptive platform trial protocol: new tools for an old foe. Clin Infect Dis. 2022;75(11):2027–2034. doi: 10.1093/cid/ciac476
   PubMed Web of Science ®Google Scholar